{"createdAt":"8/2/2020, 2:11:00 PM","timestamp":1596391860236,"Company ID number":"375","DMX_ISSUER_NAME":"Realcan Pharmaceutical Group Co., Ltd.","DMX_ISSUER_ID":"IID000000002620186","Country of Classification":"CHINA","name":"Realcan Pharmaceutical Group Co Ltd ","code":"002589","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"瑞康医药集团股份有限公司_韩旭","group":"board","name":"韩旭","title":"董事长,董事","isMale":true,"age":"55","degree":"本科","salary":"43.65万","stockAmount":"1.875亿","description":"韩旭先生:中国国籍,无境外永久居留权,1965年出生,本科学历。历任烟台二运公司职业高中教师,烟台二运公司企管科科员,山东瑞康药业有限公司董事长,山东瑞康药品配送有限公司董事长,现任瑞康医药集团股份有限公司董事长。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_张仁华","group":"board","name":"张仁华","title":"副董事长,董事","isMale":false,"age":"54","degree":"大专","salary":"43.65万","stockAmount":"2.879亿","description":"张仁华女士:中国国籍,无境外永久居留权,1966年出生,大专学历,药剂师。历任烟台山医院团总支书记,山东瑞康药业有限公司总经理,山东瑞康药品配送有限公司总经理,现任瑞康医药集团股份有限公司副董事长兼总经理,山东省人大代表。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_周云","group":"board","name":"周云","title":"董事","isMale":false,"age":"50","degree":"本科","salary":"25.10万","stockAmount":"55.51万","description":"周云女士:中国国籍,无境外永久居留权,1970年出生,本科学历。历任烟台市医药公司组织科干事,烟台市医药公司下属企业劳资主管,山东瑞康药业有限公司人力资源部经理,山东瑞康药品配送有限公司人力资源中心经理、总监、监事,现任瑞康医药集团股份有限公司董事会秘书、董事、副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_杨博","group":"board","name":"杨博","title":"董事","isMale":true,"age":"37","degree":"硕士","salary":"24.96万","stockAmount":"-","description":"杨博先生:中国国籍,无境外永久居留权,1983年出生,研究生学历。历任山东瑞康药品配送有限公司采购主管、监事、董事。现任瑞康医药集团股份有限公司董事、副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_韩春林","group":"board","name":"韩春林","title":"董事","isMale":true,"age":"27","degree":"本科","salary":"24.32万","stockAmount":"-","description":"韩春林先生:中国国籍,拥有加拿大永久居留权,1993年出生,本科学历,历任瑞康医药股份有限公司总经理助理、投融资部总经理、人力资源部总经理,现任瑞康医药集团股份有限公司董事、副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_冯红涛","group":"board","name":"冯红涛","title":"董事","isMale":true,"age":"49","degree":"硕士","salary":"0.00","stockAmount":"-","description":"冯红涛先生:中国国籍,无境外永久居留权,1971年出生,研究生学历。历任招商银行深圳南油支行对公业务员、蛇口明华海事服务中心/蛇口明华船务有限公司财务部主管、招商局集团金融事业部银行业务主管、招商局集团新加坡有限公司财务部经理、招商局集团业务开发部主任、招商局国际(青岛)码头有限公司财务总监、招商局集团业务开发部经理、招商局集团重大项目办公室副主任等职务。现任瑞康医药集团股份有限公司董事、招商局资本管理有限责任公司副总经理、中新建招商股权投资有限公司暨招商昆仑股权投资管理有限公司董事总经理兼董事会秘书、深圳市招商三新资本管理有限责任公司总经理、深圳市招商慧合股权投资基金管理有限公司总经理、荆州招商慧德资本管理有限责任公司总经理等职务。","lastUpdated":"2019-10-09"},{"id":"瑞康医药集团股份有限公司_武滨","group":"board","name":"武滨","title":"独立董事","isMale":true,"age":"60","degree":"硕士","salary":"6.000万","stockAmount":"-","description":"武滨,1960年出生,研究生,高级咨询师,执业药师。曾经历任山西省医药公司企业管理科副科长,山西省医药管理局商业处副处长,山西省药材公司副经理,山西省医药集团有限公司经济运行部部长、总经理助理;现任中国医药商业协会副会长。","lastUpdated":"2019-10-09"},{"id":"瑞康医药集团股份有限公司_于建青","group":"board","name":"于建青","title":"独立董事","isMale":true,"age":"55","degree":"本科","salary":"6.000万","stockAmount":"-","description":"于建青先生:中国国籍,无境外永久居留权,1965年生,本科学历,二级律师。历任山东省司法学校教师,山东省司法学校民法教科研室副主任,烟台市司法局宣教科科员,山东通世律师事务所律师、副主任,烟台泰和新材料股份有限公司独立董事,山东龙大肉食品股份有限公司独立董事。现任山东通世律师事务所主任,烟台仲裁委员会仲裁员,烟台杰瑞石油服务集团股份有限公司独立董事,烟台正海磁性材料股份有限公司独立董事,瑞康医药集团股份有限公司独立董事。","lastUpdated":"2019-10-09"},{"id":"瑞康医药集团股份有限公司_柳喜军","group":"board","name":"柳喜军","title":"独立董事","isMale":true,"age":"54","degree":"本科","salary":"--","stockAmount":"-","description":"柳喜军,男,汉族,1966年出生,大学本科学历,高级会计师、注册会计师、注册资产评估师、土地评估师。曾任烟台市财政局科员、烟台乾聚会计师事务所部门经理、烟台海达会计师事务所所长、山东新潮实业股份有限公司独立董事、山东鲁亿通智能电气股份有限公司独立董事,现任烟台市第十七届人民代表大会常务委员会委员,烟台嘉信有限责任会计师事务所董事长、总经理,山东嘉信安泰保险公估有限公司董事长、总经理,烟台正海磁性材料股份有限公司独立董事。","lastUpdated":"2020-03-10"},{"id":"瑞康医药集团股份有限公司_吴丽艳","group":"supervisoryCommittee","name":"吴丽艳","title":"监事会主席","isMale":false,"age":"42","degree":"大专","salary":"19.43万","stockAmount":"-","description":"吴丽艳女士:中国国籍,无境外永久居留权,1978年出生,大专学历。历任莱州市西由镇农村信用合作社信贷员,山东瑞康药业有限公司系统维护员,山东瑞康药品配送有限公司信息部经理,公司董事。现任瑞康医药集团股份有限公司数字化企业服务部总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_陶春芳","group":"supervisoryCommittee","name":"陶春芳","title":"监事","isMale":false,"age":"45","degree":"大专","salary":"11.31万","stockAmount":"-","description":"陶春芳女士:中国国籍,无境外永久居留权,1975年出生,大专学历,历任山东瑞康药品配送有限公司财务主管。现任瑞康医药集团股份有限公司销售服务部经理、监事。","lastUpdated":"2019-10-09"},{"id":"瑞康医药集团股份有限公司_黄少杰","group":"supervisoryCommittee","name":"黄少杰","title":"职工监事","isMale":true,"age":"48","degree":"中专","salary":"21.27万","stockAmount":"-","description":"黄少杰先生:中国国籍,无境外永久居留权,1972年出生,中专学历,执业药师,历任烟台永达生化制药公司质量检验员,山东瑞康药业质量检验员,瑞康配送物流管理部副经理。现任瑞康医药集团股份有限公司物流事业部总经理、职工监事。","lastUpdated":"2019-09-23"},{"id":"瑞康医药集团股份有限公司_尹世强","group":"manager","name":"尹世强","title":"总经理","isMale":true,"age":"53","degree":"硕士","salary":"8.240万","stockAmount":"-","description":"尹世强先生:中国国籍,无境外永久居留权,1967年出生,研究生学历。历任天津中医药大学第二附属医院制剂室主任、药剂科主任、副院长,国药控股天津有限公司总经理助理、副总经理,现任瑞康医药集团股份有限公司总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_周云","group":"manager","name":"周云","title":"董事会秘书,副总经理","isMale":false,"age":"50","degree":"本科","salary":"25.10万","stockAmount":"55.51万","description":"周云女士:中国国籍,无境外永久居留权,1970年出生,本科学历。历任烟台市医药公司组织科干事,烟台市医药公司下属企业劳资主管,山东瑞康药业有限公司人力资源部经理,山东瑞康药品配送有限公司人力资源中心经理、总监、监事,现任瑞康医药集团股份有限公司董事会秘书、董事、副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_杨博","group":"manager","name":"杨博","title":"副总经理","isMale":true,"age":"37","degree":"硕士","salary":"24.96万","stockAmount":"-","description":"杨博先生:中国国籍,无境外永久居留权,1983年出生,研究生学历。历任山东瑞康药品配送有限公司采购主管、监事、董事。现任瑞康医药集团股份有限公司董事、副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_韩春林","group":"manager","name":"韩春林","title":"副总经理","isMale":true,"age":"27","degree":"本科","salary":"24.32万","stockAmount":"-","description":"韩春林先生:中国国籍,拥有加拿大永久居留权,1993年出生,本科学历,历任瑞康医药股份有限公司总经理助理、投融资部总经理、人力资源部总经理,现任瑞康医药集团股份有限公司董事、副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_俞斌","group":"manager","name":"俞斌","title":"副总经理,财务总监","isMale":true,"age":"42","degree":"硕士","salary":"16.11万","stockAmount":"-","description":"俞斌先生:中国国籍,无境外永久居留权,1978年出生,上海财经大学税务专业经济学学士、国际经济法专业法学学士,美国亚利桑那州立大学凯瑞商学院金融与财务管理专业工商管理硕士。会计师。曾任上药控股有限公司财务副总监,财务与资产管理部总经理;上药康德乐(上海)医药有限公司财务总监;上海市医药股份有限公司财务总部副总经理;江西南华医药有限公司监事长;上海苏丹制药有限公司董事;上海得一医药有限公司董事等。现任瑞康医药集团股份有限公司副总经理、财务总监。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_阎明涛","group":"manager","name":"阎明涛","title":"副总经理","isMale":true,"age":"55","degree":"本科","salary":"26.25万","stockAmount":"-","description":"阎明涛先生:中国国籍,无境外永久居留权,1965年出生,本科学历,高级工程师、执业药师。历任烟台中策药业公司生产科长、销售科长,烟台益生药业有限公司副总经理,山东瑞康药业配有限公司常务副总经理,山东瑞康药品配送有限公司常务副总经理。现任瑞康医药集团股份有限公司副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_苏立臣","group":"manager","name":"苏立臣","title":"副总经理","isMale":true,"age":"48","degree":"本科","salary":"24.82万","stockAmount":"56.57万","description":"苏立臣先生:中国国籍,无境外永久居留权,1972年出生,本科学历,会计师,中国注册会计师。历任烟台市医药物资经营总公司会计、会计主管,烟台市医药公司审计、会计主管,烟台医药国有控股有限公司会计主管,山东瑞康医药股份有限公司财务经理,瑞康医药集团股份有限公司财务总监,现任瑞康医药集团股份有限公司副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_魏清义","group":"manager","name":"魏清义","title":"副总经理","isMale":true,"age":"45","degree":"本科","salary":"27.72万","stockAmount":"-","description":"魏清义先生:新加坡国籍,1975年出生,本科学历。历任甲骨文亚太地区有限公司经理,微软(中国)有限公司总监,富士施乐(中国)有限公司总监,思爱普(中国)有限公司总经理。现任瑞康医药集团股份有限公司副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_逄敏","group":"manager","name":"逄敏","title":"副总经理","isMale":false,"age":"56","degree":"大专","salary":"25.23万","stockAmount":"-","description":"逄敏女士:中国国籍,无境外永久居留权,1964年出生,专科学历。历任烟台泰来模具有限公司出纳、会计、主管会计,烟台表壳厂主管会计。山东瑞康药业有限公司主管会计、财务经理,山东瑞康药品配送有限公司审计总监、商务事业部总经理,现任瑞康医药集团股份有限公司副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_秦晓华","group":"manager","name":"秦晓华","title":"副总经理","isMale":true,"age":"40","degree":"本科","salary":"24.17万","stockAmount":"52.62万","description":"秦晓华先生:中国国籍,无境外永久居留权,1980年出生,本科学历。历任天安保险股份有限公司企划,解放日报报业集团记者、编辑,太平洋安泰人寿保险有限公司(现建信人寿)企划主管,浙商控股集团上海资产管理有限公司项目总监,中信证券股份有限公司资产管理部总监、投资主办人,现任瑞康医药集团股份有限公司副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_栾彤辉","group":"manager","name":"栾彤辉","title":"副总经理","isMale":true,"age":"53","degree":"大专","salary":"24.41万","stockAmount":"-","description":"栾彤辉先生:中国国籍,无境外永久居留权,1967年出生,大专学历。历任山东省农业机械集团青岛公司财务处副处长,青岛宝康生物科技有限公司总经理,现任瑞康医药集团股份有限公司副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_彭易奎","group":"manager","name":"彭易奎","title":"副总经理","isMale":true,"age":"45","degree":"本科","salary":"25.67万","stockAmount":"-","description":"彭易奎先生:中国国籍,无境外永久居留权,1975年出生,本科学历。历任浙江省医药供销公司销售员,浙江康大医疗设备有限公司销售主管,江西康大医疗设备有限公司总经理,南昌普健实业有限公司总经理,现任瑞康医药集团股份有限公司副总经理、检验事业部总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_刘廷利","group":"manager","name":"刘廷利","title":"副总经理","isMale":true,"age":"50","degree":"本科","salary":"25.08万","stockAmount":"-","description":"刘廷利先生:中国国籍,1970年出生,本科学历。历任莱州市粮食收储管理中心西由收储站主管会计,莱州市梁郭粮食管理所主管会计,北京同仁堂山东医药连锁有限公司主管会计,山东瑞康药品配送有限公司审计总监,现任瑞康医药集团股份有限公司副总经理,审计部总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_李喆","group":"manager","name":"李喆","title":"副总经理","isMale":true,"age":"34","degree":"硕士","salary":"24.40万","stockAmount":"-","description":"李喆先生:中国国籍,无境外永久居留权,1986年出生,硕士学历。历任加拿大永明金融蒙特利尔分部理财顾问、加拿大帝国商业银行多伦多分部基金管理专员、国金证券上海承销保荐分公司投行项目经理,现任瑞康医药集团股份有限公司副总经理、资金管理部总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_张寿凯","group":"manager","name":"张寿凯","title":"副总经理","isMale":true,"age":"34","degree":"硕士","salary":"24.13万","stockAmount":"-","description":"张寿凯先生:中国国籍,拥有加拿大永久居留权,1986年出生,硕士学历。在海外期间创办HAIXIN公司从事境外投资及BOT业务运营。现任瑞康医药集团股份有限公司副总经理。","lastUpdated":"2019-10-31"},{"id":"瑞康医药集团股份有限公司_周其涛","group":"manager","name":"周其涛","title":"副总经理","isMale":true,"age":"52","degree":"大专","salary":"24.27万","stockAmount":"-","description":"周其涛先生:中国国籍,无境外永久居留权,1968年出生,大专学历。历任烟台中策药业有限公司大区经理,国药控股烟台有限公司副总经理,华润烟台医药有限公司常务副总经理,现任瑞康医药集团股份有限公司副总经理。","lastUpdated":"2019-10-31"}],"companyName":"瑞康医药集团股份有限公司","province":"山东省","englishName":"Realcan Pharmaceutical Group Co Ltd","industry":"医药生物 — 医药商业Ⅱ","website":"www.realcan.cn","mainBusiness":"药品销售","productsName":["药品","器械-检验","器械-介入","器械-普耗及器械配送","器械-其他产品线","移动医疗"],"actualController":"张仁华、韩旭","actualControllerSharePercentage":"19.13、12.46%","registeredCapital":"15.05亿元","employeeAmount":"10011","phone":"86-0535-6737695","location":"山东省烟台市芝罘区机场路326号","chineseDescription":"瑞康医药集团股份有限公司的主营业务为药品销售。其主要产品有药品、器械-检验、器械-介入、器械-普耗及器械配送、器械-其他产品线、移动医疗。公司目前已发展成一家全国性药品、医疗器械流通行业的领军企业之一,在中国医药商业协会公布的最新一期医药流通企业销售排名第七。对医疗机构直销业务规模在全国民营医疗企业中处于领先地位,IVD业务规模在全国处于领先地位。","foundedDate":"2004-09-21","goPublicDate":"2011-06-10","companyHistory":"瑞康医药集团股份有限公司（以下简称“瑞康医药”或“公司”“本公司”)系由山东瑞康药品配送有限公司（以下简称“瑞康配送”)整体变更设立，公司股本演变情况如下：\n　　2004年9月21日，自然人张仁华、韩旭共同出资300万元，设立烟台瑞康药品配送有限公司（以下简称“烟台瑞康配送”)，其中张仁华出资267.54万元，韩旭出资32.46万元。\n　　2005年2月2日，烟台瑞康配送股东会通过决议，同意公司注册资本从300万元增加到600万元，增资部分全部由山东瑞康药业有限公司（以下简称“瑞康药业”)以土地使用权出资。\n　　2005年4月22日，韩旭与张仁华签署股权转让协议，将其持有的烟台瑞康配送32.46万元股权（占注册资本5.41%）以原始出资额作价全部转让给张仁华，同日，烟台瑞康配送股东会通过了同意股权转让的决议。\n　　2005年6月8日，烟台瑞康配送股东会通过决议，同意公司注册资本从600万元增加到1,015万元，增加部分415万元，由崔胜利认缴315万元、焦翠英认缴100万元，均以货币资金认缴。\n　　2005年8月28日，烟台瑞康配送股东会通过决议，同意公司注册资本从1,015万元增加到1,455万元，增加部分440万元全部由焦翠英以货币资金认缴。\n　　2006年4月24日，烟台瑞康配送股东会通过决议，同意公司注册资本从1,455万元增加到2,000万元，增加部分的注册资本由张仁华认缴142万元、焦翠英认缴254万元、崔胜利认缴149万元，股东均以现金出资。\n　　2006年9月1日，瑞康配送股东会通过决议，同意将公司名称从烟台瑞康药品配送有限公司变更为山东瑞康药品配送有限公司（以下简称“瑞康配送”）。\n　　2007年4月6日，崔胜利与韩旭签订股权转让协议，将其持有的瑞康配送464万元股权（占注册资本23.2%）全部转让给韩旭；同日，焦翠英与韩旭、张仁华分别签订股权转让协议，将其持有的瑞康配送556万元股权（占注册资本27.8%）和238万元股权（占注册资本11.9%）分别转让给韩旭、张仁华。\n　　2007年4月6日，瑞康配送股东会通过决议，同意公司注册资本从2,000万元增加到3,000万元，增加部分的注册资本1,000万元由韩旭投入600万元、张仁华投入400万元。\n　　2007年10月17日，瑞康药业与张仁华签署股权转让协议，将其持有的公司300万元股权转让给张仁华。\n　　2008年2月25日，瑞康配送股东会通过决议，将公司注册资本从3,000万元增加至5,000万元，增加的2,000万元注册资本中，张仁华认缴570万元、韩旭认缴180万元、徐厚华认缴550万元、李冬青认缴100万元、吴良禄认缴30万元、李秉浩认缴320万元、蔡文伟认缴250万元，均以现金增资。上述认缴方均按照1.8元/每单位注册资本的价格认缴增资，共计缴纳增资款3,600万元，其中2,000万元计入注册资本，1,600万元进入资本公积。本次增资后，公司注册资本变更为5,000万元。\n　　2008年3月20日，蔡文伟与师平签署出资转让协议书，将其持有的公司100万元股权（占注册资本2%）以180万元转让给师平。\n　　2009年3月20日，徐厚华、李冬青、吴良禄分别与张仁华签署出资转让协议书，将其分别持有的瑞康配送550万元出资（占注册资本11%）、100万元出资（占注册资本2%）、30万元出资（占注册资本0.6%）转让给张仁华，转让价格分别为990万元、180万元和54万元。\n　　2009年5月26日，师平与蔡文伟签订股权转让协议，将其持有的瑞康配送100万元股权（占注册资本2%）以180万元转让给蔡文伟。\n　　2009年7月1日，李秉浩与外国投资者TBNatureLimited签订了股权转让协议，将其持有的全部瑞康配送6.4%的股权（即注册资本中的320万元）以1,496万元人民币的价格转让给TBNatureLimited。同日，蔡文伟与外国投资者TBNatureLimited签订了《股权转让协议》，将其持有的全部瑞康配送5%的股权（即注册资本中的250万元）以1,168万元人民币的价格转让给TBNatureLimited。同日，公司股东会通过了同意上述股权转让的决议，并通过了将公司注册资本从5,000万元增加到5,886万元的决议，增资部分全部由TBNatureLimited以7,740万元人民币的价格认购，同时公司性质变更为港澳台与内资合资经营的有限责任公司。\n　　2009年10月16日，张仁华与青岛睿华方略医药咨询服务有限公司（以下简称“青岛睿华方略”）签署协议书，将其持有公司的出资额353万元（占公司注册资本的6%）作价3,320.10万元转让给青岛睿华方略。\n　　2009年11月15日，瑞康配送董事会通过决议，同意将公司整体变更为股份有限公司，整体变更后的公司名称为山东瑞康医药股份有限公司，并根据北京天圆全会计师事务所有限公司出具的“天圆全审字[2009]495号”审计报告，以审计基准日2009年10月31日经审计的净资产22,193.11万元，按照1：0.3154的折股比例折为7,000万股，余下未折为股份的15,193.11万元计入资本公积。\n　　经中国证券监督管理委员会证监许可【2011】779号文《关于核准山东瑞康医药股份有限公司首次公开发行股票的批复》核准,公司由主承销商平安证券有限公司采用网下向询价对象询价配售与网上资金申购定价发行相结合的方式发行人民币普通股2,380万股,发行价格20.00元/股,募集资金总额人民币476,000,000.00元,扣除发行费用人民币40,906,662.66元,实际募集资金净额435,093,337.34元。\n　　2011年6月8日,经深圳证券交易所《关于山东瑞康医药股份有限公司人民币股票上市的通知》深证上[2011]174号文同意,公司发行的人民币普通股股票在深圳证券交易所上市交易。其中,公司发行中上网定价公开发行的1,904万股人民币普通股股票自2011年6月10日起在深圳证券交易所上市交易。\n　　本次公开发行股票后,公司的股本由人民币7,000万元变更为9,380万元。\n　　经中国证券监督管理委员会证监许可[2013]866号文《关于核准山东瑞康医药股份有限公司非公开发行股票的批复》的核准，同意公司非公开发行普通股（A股）股数1,514.76万股。截至2013年10月18日止，公司通过向平安大华基金管理有限公司等股东发行人民币普通股（A）股1,514.76万股，公司变更后的累计注册资本为人民币10,894.76万元，股本为人民币10,894.76万元。\n　　公司法定代表人:韩旭公司住所：烟台市芝罘区机场路326号。收起▲","shareholders":[{"organizationId":"","holderName":"张仁华","totalShare":"2.88亿","sharePercentage":"19.13%"},{"organizationId":"","holderName":"韩旭","totalShare":"1.87亿","sharePercentage":"12.46%"},{"organizationId":"T004827642","holderName":"荆州招商慧泽医药投资合伙企业(有限合伙)","totalShare":"7523.55万","sharePercentage":"5.00%"},{"organizationId":"","holderName":"汇添富基金-工商银行-汇添富-优势医药企业定增计划4号资产管理计划","totalShare":"3307.42万","sharePercentage":"2.20%"},{"organizationId":"","holderName":"汇添富基金-工商银行-汇添富-优势医药企业定增计划5号资产管理计划","totalShare":"3307.42万","sharePercentage":"2.20%"},{"organizationId":"T004862841","holderName":"江阴毅达高新股权投资合伙企业(有限合伙)","totalShare":"3044.12万","sharePercentage":"2.02%"},{"organizationId":"T004830409","holderName":"宁波梅山保税港区红杉贤盛股权投资合伙企业(有限合伙)","totalShare":"3009.42万","sharePercentage":"2.00%"},{"organizationId":"T000160507","holderName":"长城国融投资管理有限公司","totalShare":"2684.57万","sharePercentage":"1.78%"},{"organizationId":"","holderName":"中国人民人寿保险股份有限公司-传统-普通保险产品","totalShare":"2553.61万","sharePercentage":"1.70%"},{"organizationId":"","holderName":"汇添富基金-宁波银行-程义全","totalShare":"1320.21万","sharePercentage":"0.88%"}],"englishDescription":"Realcan Pharmaceutical Group Co., Ltd., formerly REALCAN PHARMACEUTICAL CO., LTD., is a China-based medical service provider. The Company operates its businesses through three segments. The Medical segment is engaged in the provision of Chinese medicine materials, Chinese medicine tablets, Chinese patent medicines, chemical drug materials, chemical preparations, antibiotics, biochemical pharmaceuticals, biological products, psychotropic substances, anesthetic medicines and peptide hormones. The Equipment is engaged in the provision of medical equipment. The Mobile Medical segment is engaged in the provision of medical and logistics services and mobile medical information services. The Company conducts its businesses mainly within domestic markets, with Shandong as its main market.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"--","Price to sales (ttm)":"0.31","Price to book (mrq)":"1.37","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"197.97","Lt debt to equity (mrq)":"18.63","Return on investment (ttm)":"-5.73","Return on equity (ttm)":"-1.58","Income statement":{},"Balance sheet":{"Cash":"11.62","Cash & equivalents":"4,818.80","Short term investments":"323.23","Cash and short term investments":"5,153.65","Accounts receivable - trade, net":"15,638.58","Total receivables, net":"17,547.74","Total inventory":"3,647.60","Prepaid expenses":"1,178.59","Other current assets, total":"229.63","Total current assets":"27,757.22","Property/plant/equipment, total - gross":"3,462.59","Accumulated depreciation, total":"(781.05)","Property/plant/equipment, total - net":"2,681.54","Goodwill, net":"1,263.92","Intangibles, net":"219.68","Long term investments":"261.81","Other long term assets, total":"281.11","Total assets":"32,465.27","Accounts payable":"5,303.50","Accrued expenses":"178.50","Notes payable/short term debt":"11,685.08","Current port. of  lt debt/capital leases":"55.27","Other current liabilities, total":"3,437.75","Total current liabilities":"20,660.09","Long term debt":"1,326.48","Total long term debt":"1,326.48","Total debt":"13,066.83","Deferred income tax":"203.10","Minority interest":"3,066.25","Other liabilities, total":"22.85","Total liabilities":"25,278.78","Common stock, total":"1,504.71","Additional paid-in capital":"3,950.48","Retained earnings (accumulated deficit)":"1,961.95","Treasury stock - common":"(230.65)","Total equity":"7,186.49","Total liabilities & shareholders' equity":"32,465.27","Total common shares outstanding":"1,504.71","Tangible book value per share, common eq":"3.79","Capital lease obligations":"1.64"},"Cash flow":{"Cash receipts":"35,153.61","Cash payments":"(28,102.30)","Cash taxes paid":"(1,651.10)","Changes in working capital":"(3,305.68)","Cash from operating activities":"2,094.52","Capital expenditures":"(934.87)","Other investing cash flow items, total":"(383.75)","Cash from investing activities":"(1,318.63)","Financing cash flow items":"1,750.24","Total cash dividends paid":"(499.64)","Issuance (retirement) of debt, net":"(1,518.60)","Cash from financing activities":"(268.00)","Net change in cash":"507.90","Foreign exchange effects":"0.15"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"6.62","52 Week High":"9.27","52 Week Low":"5.01","Pricing date":"","10 Day Average Trading Volume":"33.00","Market Capitalization":"9,961.18","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"432.18","Beta":"0.95","1 Day Price Change":"5.25","13 Week Price Return (Daily)":"28.54","26 Week Price Return (Daily)":"-4.89","5 Day Price Return (Daily)":"16.55","52 Week Price Return (Daily)":"-15.13","Year To Date Price Return (Daily)":"-13.91","Month to Date Price Return (Daily)":"23.51","Price Relative to S&P500 (4 Week)":"9.33","Price Relative to S&P500 (13 Week)":"1.06","Price Relative to S&P500 (26 Week)":"-25.50","Price Relative to S&P500 (52 Week)":"-42.32","Price Relative to S&P500 (YTD)":"-34.16"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"-0.62","EPS excl. Extra Items (TTM)":"-0.70","EPS Normalized (Annual)":"0.12","Revenue per Share (Annual)":"23.56","Revenue per Share (TTM)":"21.27","Book Value (Per Share Annual)":"4.78","Book Value (Per Share Quarterly)":"4.84","Tangible Book Value (Per Share Annual)":"3.79","Tangible Book Value (Per Share Quarterly)":"3.86","Cash Per Share (Per Share Annual)":"3.43","Cash Per Share (Per Share Quarterly)":"4.73","Cash Flow (Per Share Annual)":"-0.11","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.00","Dividends (Per Share TTM)":"0.00","EBITD (Per Share TTM)":"0.29","EPS Basic excl. Extra Items (Annual)":"-0.62","EPS Basic excl. Extra Items (TTM)":"-0.70","EPS incl. Extra Items (Annual)":"-0.62","EPS incl. Extra Items (TTM)":"-0.70","Free Cash Flow (Per Share TTM)":"0.40","Dividend (Per Share 5Y)":"0.04"},"Valuation":{"P/E excl. Extra Items (Annual)":"--","P/E excl. Extra Items (TTM)":"--","P/E Normalized (Annual)":"53.90","Price to sales (Annual)":"0.28","Price to sales (TTM)":"0.31","Price to Tangible Book (Annual)":"1.75","Price to Tangible Book (Quarterly)":"1.72","Price to Free Cash Flow (Per Share Annual)":"15.09","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"16.51","Price to Book (Annual)":"1.39","Price to Book (Quarterly)":"1.37","P/E Basic excl. Extra Items (TTM)":"--","P/E excl. Extra Items High (TTM)":"81.43","P/E excl. Extra Items Low (TTM)":"13.43","P/E incl. Extra Items (TTM)":"--","Net Debt (Interim)":"7,304.48","Net Debt (Annual)":"7,913.17","Dividend Yield (5Y)":"0.31","Dividend Yield":"--","Current Dividend Yield (TTM)":"0.00"},"Financial Strength":{"Free Cash Flow (Annual)":"660.01","Current Ratio (Annual)":"1.34","Net Interest coverage (Annual)":"4.62","Long Term Debt/Equity (Annual)":"18.46","Payout Ratio (Annual)":"--","Quick Ratio (Annual)":"1.17","Total Debt/Total Equity (Annual)":"181.82","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.33","Long Term Debt/Equity (Quarterly)":"18.63","Quick Ratio (Quarterly)":"1.17","Total Debt/Total Equity (Quarterly)":"197.97","Free Cash Flow (TTM)":"603.47","Net Interest Coverage (TTM)":"0.83","Payout Ratio (TTM)":"--"},"Margins":{"Gross Margin (Annual)":"19.34","Gross Margin (TTM)":"19.03","Net Profit Margin % (Annual)":"-1.23","Net Profit Margin (TTM)":"-1.74","Operating Margin (Annual)":"0.38","Operating Margin (TTM)":"-0.23","Pretax Margin (TTM)":"-0.37","Pretax Margin (Annual)":"0.29","Operating Margin (5Y)":"4.32","Pretax Margin (5Y)":"4.30","Free Operating Cash Flow/Revenue (5Y)":"-5.57","Free Operating Cash Flow/Revenue (TTM)":"1.87","Gross Margin (5Y)":"17.93","Net Profit Margin (5Y)":"2.65"},"Management Effectiveness":{"Return on Assets (Annual)":"-1.29","Return on Equity (TTM)":"-1.58","Return on Average Equity (Annual)":"-11.84","Return on Average equity (TTM)":"-12.85","Return on Investment (Annual)":"-4.47","Return on Investment (TTM)":"-5.73","Return on Average Assets (5Y)":"2.96","Return on Average Equity (5Y)":"5.44","Return on Investment (5Y)":"8.77","Asset Turnover (Annual)":"1.05","Asset Turnover (TTM)":"0.91","Inventory Turnover (Annual)":"6.98","Inventory Turnover (TTM)":"6.77","Net Income/Employee (Annual)":"-43,264.37","Net Income/Employee (TTM)":"-55,966.18","Receivables Turnover (Annual)":"2.15","Receivables Turnover (TTM)":"1.94","Revenue/Employee (Annual)":"3,506,914.00","Revenue/Employee (TTM)":"3,224,500.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-34.07","Revenue Growth Rate (5Y)":"35.27","EPS Growth (Quarterly YoY)":"-52.45","EPS Growth (TTM YoY)":"-256.67","EPS Growth Rate (5Y)":"--","Dividend Growth Rate (3Y)":"--","Revenue Growth (TTM YoY)":"-9.15","Revenue Growth (Per Share 5Y)":"24.85","Revenue Growth Rate (3Y)":"31.18","EPS Growth Rate (3Y)":"--","Book Value Growth Rate (Per Share 5Y)":"21.64","Tangible Book Value Total Equity CAGR (5Y)":"27.90","Capital Spending growth rate 5 year":"38.53","EBITDA CAGR (5Y)":"51.16","EBITDA Interim CAGR (5Y)":"6.26","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"51.97","Net Profit Margin Growth Rate (5Y)":"--"},"Income Statement":{"Revenue (Annual)":"35,258.51","Revenue (TTM)":"32,280.46","EBITD (Annual)":"2,629.19","EBITD (TTM)":"437.00","Earnings Before Taxes (Annual)":"102.38","Earnings Before Taxes (TTM)":"-120.00","Net Income to Common (Annual)":"-927.80","Net Income to Common (TTM)":"-1,022.07","Earnings Before Taxes Normalized (Annual)":"1,812.51","Net Income Available to Common Normalized (Annual)":"183.79","Diluted Normalized EPS excl. Extra Items (TTM)":"-0.71"}}}